Gastric Ulcers Market Report 2025

This Gastric Ulcers market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The gastric ulcers market size has grown strongly in recent years. It will grow from $4.29 billion in 2024 to $4.54 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to the rising prevalence of helicobacter pylori infections, increasing use of nonsteroidal anti-inflammatory drugs (NSAIDs), growing geriatric population globally, rising awareness campaigns for gastric ulcer prevention and increasing incidence of stress-related disorders.

The gastric ulcers market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to improvements in diagnostic techniques, adoption of unhealthy dietary habits, advancements in treatment options, including proton pump inhibitors (PPIs), aging population contributing to higher disease burden and expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include shift towards combination therapies for enhanced efficacy, growing preference for minimally invasive treatment procedures, integration of digital health solutions in disease management, rising demand for over-the-counter (OTC) ulcer medications and expansion of personalized medicine approaches in ulcer treatment.

The growing geriatric population is expected to drive the growth of the gastric ulcers market in the coming years. The geriatric population refers to individuals typically aged 65 and older, who face unique health challenges associated with aging. This increase is primarily due to advancements in healthcare, which have led to longer life expectancies, alongside declining birth rates in many regions worldwide. Gastric ulcers are more common among the elderly due to the frequent use of NSAIDs and reduced mucosal protection, both of which heighten the risk of complications. For example, in January 2024, the Population Reference Bureau (PRB), a US-based non-profit organization, reported that the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. Moreover, this age group’s share of the total population is projected to rise from 17% to 23%, highlighting a significant aging trend in the U.S. population. These projections emphasize the growing need to address the healthcare needs of older adults across various sectors. As such, the increasing geriatric population is driving the growth of the gastric ulcers market.

Key companies in the gastric ulcer market are focusing on developing innovative products, such as new drug formulations, to improve treatment effectiveness and minimize side effects. New formulation drugs involve the creation of medications with novel combinations of active ingredients, delivery methods, or dosage forms aimed at enhancing their efficacy, safety, and patient adherence. For example, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturer, introduced Rabeprazole + Levosulpiride SR Capsules. These capsules are designed to provide better relief for conditions like gastro-oesophageal reflux disease (GERD) and other gastrointestinal tract (GIT) disorders. The combination of a proton pump inhibitor and a prokinetic agent effectively treats gastrointestinal issues, including GERD and gastric ulcers. This formulation not only decreases gastric acid secretion but also improves gastric motility, offering comprehensive relief from symptoms such as heartburn and indigestion.

In May 2022, Dr. Reddy's Laboratories partnered with HK Inno.N. Corporation to supply and commercialize Tegoprazan, a novel molecule for gastrointestinal diseases, in India and six key emerging markets. Under this partnership, HK Inno.N. will manufacture and supply Tegoprazan, while Dr. Reddy's will oversee local clinical development, registration, marketing, and sales in the licensed territories. HK Inno.N. Corporation is a South Korea-based pharmaceutical company specializing in drugs for gastric ulcers.

Major companies operating in the gastric ulcers market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd, Amgen Inc., Boehringer Ingelheim, Viatris Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd, Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Yuhan Corporation, Daewoong Pharmaceutical Co. Ltd, Cadila Healthcare Ltd, Novitium Pharma LLC.

North America was the largest region in the gastric ulcers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric ulcers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric ulcers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastric ulcers, also known as peptic ulcers, are open sores on the stomach's inner lining caused by the corrosive action of stomach acid. They often result in burning stomach pain, indigestion, and discomfort. These ulcers typically arise from an imbalance between stomach acid, the enzyme pepsin, and the protective mucosal barrier lining the stomach and duodenum.

The primary drug classes used to treat gastric ulcers include proton pump inhibitors (PPIs), H2 antagonists, antacids, antibiotics, cytoprotective agents, and others. Proton pump inhibitors are medications that reduce stomach acid production by inhibiting the proton pump enzyme in gastric cells. Gastric ulcers can be diagnosed through stool tests, endoscopies, imaging tests, computed tomography (CT) scans, X-rays, blood tests, and other methods. Treatment routes include oral and parenteral administration, among others. Distribution channels primarily consist of hospital pharmacies, retail pharmacies, and online pharmacies, and the treatments are utilized by various end-users such as hospitals, specialty clinics, and homecare settings.

The gastric ulcers market research report is one of a series of new reports that provides gastric ulcers market statistics, including gastric ulcers industry global market size, regional shares, competitors with a gastric ulcers market share, detailed gastric ulcers market segments, market trends and opportunities, and any further data you may need to thrive in the gastric ulcers industry. This gastric ulcers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric ulcers market consists of revenues earned by entities through barium swallow, H. pylori testing, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric ulcers market also includes sales of amoxicillin, clarithromycin, metronidazole, omeprazole, and lansoprazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.